Abstract
Piracetam is a drug which has been marketed in several countries for many years as a “nootropic” agent (that is, a drug which has metabolic activity on human brain), and for the treatment of myoclonus. Recently, a Cochrane review has been published on efficacy of piracetam on ameliorating language in aphasic stroke patients; the drug has been reconsidered for acute stroke treatment as well. The objective of this review was to assess the effects of piracetam in acute presumed ischemic stroke. Randomized trials comparing piracetam with control, with at least mortality reported and entry to the trial within ≈48 hours of stroke onset. Two reviewers (S.R., M.G.C.) extracted data and assessed trial quality, and this was checked by the other 2 …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
